The clinical value of nanocarbon suspension and methylene blue in sentinel lymphatic tracing and pathologic fine sorting of penile cancer: a multicentre prospective study

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

To compare nanocarbon suspension and methylene blue as lymphatic tracers in inguinal lymph node mapping and sorting during surgery for penile cancer.

Who Took Part

The study group was 62 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, men only.

This multicentre study included 62 patients (2020-2024); 33 underwent sentinel lymph node biopsy (SLNB) and 29 underwent inguinal lymph node dissection (ILND).

SLNB patients were divided into control (no tracer), nanocarbon, or methylene blue groups (ChiCTR2200063416).

How the Study Was Run

The design is described as randomized and multicenter.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

More than one site took part, so the patients came from several places.

Outcomes included lymph node detection rate (LNDR), number of lymph nodes per side (NOLNPIS), metastasis positive rate (PROLM), and operation time (OT).

ILND patients were grouped into nanocarbon-assisted sorting (NLFLNSG) or traditional sorting (TLNSG), with comparisons of NOLNPIS, PROLM, OT, and lymphatic leakage rate (PLLR).

What Was Measured

PubMed files the paper under topics including Lymph Node Excision, Lymph Nodes, Lymphatic Metastasis, Methylene Blue, Penile Neoplasms, Sentinel Lymph Node and Sentinel Lymph Node Biopsy.

Author keywords: Nanocarbon suspension, fine sorting, lymphatic tracing and penile cancer.

What This Means in Plain Language

The paper is a randomized and multicenter study of Methylene blue (non-peptide stack partner) in 62 patients.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Annals of medicine), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.